Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines

Neha Mehta-Shah; Steven M. Horwitz; Stephen Ansell; Weiyun Z. Ai; Jeffrey Barnes; Stefan K. Barta; Mark W. Clemens; Ahmet Dogan; Kristopher Fisher; Aaron M. Goodman; Gaurav Goyal; Joan Guitart; Ahmad Halwani; Bradley M. Haverkos; Richard T. Hoppe; Eric Jacobsen; Deepa Jagadeesh; Matthew A. Lunning; Amitkumar Mehta; Elise A. Olsen; Barbara Pro; Saurabh A. Rajguru; Satish Shanbhag; Aaron Shaver; Andrei Shustov; Lubomir Sokol; Pallawi Torka; Carlos Torres-Cabala; Ryan Wilcox; Basem M. William; Jasmine Zain; Mary A. Dwyer; Hema Sundar; Youn H. Kim

doi:10.6004/jnccn.2020.0022

Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines

Neha Mehta-Shah, Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Kristopher Fisher, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Matthew A. Lunning, Amitkumar Mehta, Elise A. OlsenBarbara Pro, Saurabh A. Rajguru, Satish Shanbhag, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar, Youn H. Kim

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

Original language	English (US)
Pages (from-to)	522-536
Number of pages	15
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2020.0022
State	Published - May 2020

Funding

This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc.

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2020.0022

Cite this

Mehta-Shah, N., Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Clemens, M. W., Dogan, A., Fisher, K., Goodman, A. M., Goyal, G., Guitart, J., Halwani, A., Haverkos, B. M., Hoppe, R. T., Jacobsen, E., Jagadeesh, D., Lunning, M. A., Mehta, A., ... Kim, Y. H. (2020). Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 18(5), 522-536. https://doi.org/10.6004/jnccn.2020.0022

@article{762261593aee4d8a9399109cf9d3ea69,

title = "Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines",

abstract = "Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and S{\'e}zary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).",

author = "Neha Mehta-Shah and Horwitz, {Steven M.} and Stephen Ansell and Ai, {Weiyun Z.} and Jeffrey Barnes and Barta, {Stefan K.} and Clemens, {Mark W.} and Ahmet Dogan and Kristopher Fisher and Goodman, {Aaron M.} and Gaurav Goyal and Joan Guitart and Ahmad Halwani and Haverkos, {Bradley M.} and Hoppe, {Richard T.} and Eric Jacobsen and Deepa Jagadeesh and Lunning, {Matthew A.} and Amitkumar Mehta and Olsen, {Elise A.} and Barbara Pro and Rajguru, {Saurabh A.} and Satish Shanbhag and Aaron Shaver and Andrei Shustov and Lubomir Sokol and Pallawi Torka and Carlos Torres-Cabala and Ryan Wilcox and William, {Basem M.} and Jasmine Zain and Dwyer, {Mary A.} and Hema Sundar and Kim, {Youn H.}",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.",

year = "2020",

month = may,

doi = "10.6004/jnccn.2020.0022",

language = "English (US)",

volume = "18",

pages = "522--536",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "5",

}

Mehta-Shah, N, Horwitz, SM, Ansell, S, Ai, WZ, Barnes, J, Barta, SK, Clemens, MW, Dogan, A, Fisher, K, Goodman, AM, Goyal, G, Guitart, J, Halwani, A, Haverkos, BM, Hoppe, RT, Jacobsen, E, Jagadeesh, D, Lunning, MA, Mehta, A, Olsen, EA, Pro, B, Rajguru, SA, Shanbhag, S, Shaver, A, Shustov, A, Sokol, L, Torka, P, Torres-Cabala, C, Wilcox, R, William, BM, Zain, J, Dwyer, MA, Sundar, H & Kim, YH 2020, 'Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 5, pp. 522-536. https://doi.org/10.6004/jnccn.2020.0022

TY - JOUR

T1 - Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines

AU - Mehta-Shah, Neha

AU - Horwitz, Steven M.

AU - Ansell, Stephen

AU - Ai, Weiyun Z.

AU - Barnes, Jeffrey

AU - Barta, Stefan K.

AU - Clemens, Mark W.

AU - Dogan, Ahmet

AU - Fisher, Kristopher

AU - Goodman, Aaron M.

AU - Goyal, Gaurav

AU - Guitart, Joan

AU - Halwani, Ahmad

AU - Haverkos, Bradley M.

AU - Hoppe, Richard T.

AU - Jacobsen, Eric

AU - Jagadeesh, Deepa

AU - Lunning, Matthew A.

AU - Mehta, Amitkumar

AU - Olsen, Elise A.

AU - Pro, Barbara

AU - Rajguru, Saurabh A.

AU - Shanbhag, Satish

AU - Shaver, Aaron

AU - Shustov, Andrei

AU - Sokol, Lubomir

AU - Torka, Pallawi

AU - Torres-Cabala, Carlos

AU - Wilcox, Ryan

AU - William, Basem M.

AU - Zain, Jasmine

AU - Dwyer, Mary A.

AU - Sundar, Hema

AU - Kim, Youn H.

N1 - Publisher Copyright: © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

PY - 2020/5

Y1 - 2020/5

N2 - Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

AB - Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

UR - http://www.scopus.com/inward/record.url?scp=85084397233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084397233&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0022

DO - 10.6004/jnccn.2020.0022

M3 - Article

C2 - 32380458

AN - SCOPUS:85084397233

SN - 1540-1405

VL - 18

SP - 522

EP - 536

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this